1479 / 1835
RT in GHSG BEACOPP Studies (2)
•
HD15
(Engert et al. Lancet 2012
)
showed that BEACOPP X6 was as
effective and less toxic than BEACOPP X8. OS was better due to less
treatment related toxic deaths.
•
PET was used for post-chemo evaluation, if residual CT abnormality
(39% of patients).
•
There was no randomization to +/- IFRT.
•
RT was given only to PET-positive patients (30% of those who had
PET). Total receiving RT was 11% compared to 71% in HD9.
•
PET- negative patients had outcome similar to CT evaluated CR/Cru
and better that those with residual PET.
•
PET (-) had a negative predictive value of 94%.
.
23